Clinical Genomics closed $15M financing round for colorectal cancer recurrence blood test: 4 points

Clinical Genomics recently closed a $15 million series A financing round.

Here are four points:

1. The funds will be used to advance commercialization of the company's two-gene blood test for post-surgical monitoring of colorectal cancer recurrence.

2. The blood test aims to detect tumor-specific methylated DNA biomarkers that leak from active lesions into the circulatory system.

3. The financing is being led by OneVentures, a venture capital firm.

4. Paul Kelly, MD, partner and managing director of OneVentures, will join Clinical Genomics' board of directors in connection with the financing.

More articles on GI/endoscopy:
Stay ahead of the quality-reporting game: Leverage data to maximize outcomes & reimbursement
Boston Scientific launches AXIOS Stent, EndoGastric Solutions presents promising 3-year TIF data — 6 GI company key notes
El Camino Hospital launches 1st GutCheck System trial: 4 points

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers